Gene-Edited IPSCs

Gene-edited iPSCs (induced pluripotent stem cells) are iPSCs that have been modified using precise gene-editing technologies such as CRISPR/Cas9, TALENs, or zinc-finger nucleases (ZFNs). These cells combine the advantages of iPSCs—pluripotency and differentiation potential—with targeted genetic modifications.

Content

Reprogramming:
- Derive iPSCs from patient somatic cells or commercially available sources.
Gene Editing:
- Design: Target selection using bioinformatics tools to minimize off-target effects.
- Editing Tools:
  - CRISPR/Cas9 plasmid or ribonucleoprotein (RNP) delivery.
- Delivery Methods:
  - Electroporation, nucleofection, or viral vectors.
- Selection:
  - Antibiotic resistance or fluorescence-based sorting to isolate edited cells.

Applications

Disease Modeling:
- Reproduce disease-relevant mutations in iPSCs to study pathogenesis.
- Generate isogenic controls for comparative studies.
Therapeutic Development:
- Test gene-corrected iPSCs for cell replacement therapies.
- Screen for drug candidates using gene-edited iPSC-derived cell models.
Functional Genomics:
- Study gene function and regulatory networks through knockouts, knock-ins, or base editing.
Precision Medicine:
- Model patient-specific genetic variants for personalized treatment strategies.

Gene-edited iPSCs represent a groundbreaking convergence of stem cell and gene-editing technologies. Their ability to mimic genetic diseases, explore functional genomics, and facilitate therapeutic development positions them as pivotal tools in advancing precision medicine and biotechnology research.